A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael Boyle, David M. Rodman, Steven M. Rowe et al.|The Lancet Respiratory Medicine|2014Cited by 442
Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosaAlexander Simonis, Jan Rybniker, Christoph Kreer et al.|Cell|2023Cited by 55